Veterinary Renal Diseases Market Size

Veterinary Renal Diseases Market Analysis

The Veterinary Renal Diseases Market size is estimated at USD 1.7 billion in 2024, and is expected to reach USD 2.5 billion by 2029, growing at a CAGR of 7.53% during the forecast period (2024-2029).

The veterinary renal diseases market is driven by the increasing incidences of renal diseases in animals, the widespread use of pet food as a treatment for renal diseases, the prevalence of kidney stones and cystitis in animals, and campaigns to raise awareness of diseases. The market is expected to grow due to an increase in diagnoses driven by the expanded use of imaging and blood work procedures. Veterinarians utilize blood tests and urine analysis (urinalysis) to assess animal kidney function by measuring the amounts of waste products and other substances that normally get filtered or managed by healthy kidneys. Further examinations, such as radiography (X-rays), abdominal ultrasounds, and, in certain cases, microscopic analysis of biopsy samples, may aid in the assessment of an animal that may have renal issues.

The surge in the incidences of chronic kidney diseases among cats and dogs is also expected to boost the growth of the market in the coming years. According to information released by the MSD Veterinary Manual in October 2022, chronic kidney diseases are usually incurable and commonly progress, and these diseases frequently take months or years for symptoms to manifest. It is more prevalent in animals between the ages of five and six. Chronic kidney disease (CKD) is a prevalent condition in pets, affecting up to 10% of dogs and 35% of cats globally. This high incidence underscores the need for effective diagnostic and treatment strategies. The prevalence of small animals in the general population is less than 1% or 3%.

Moreover, the COVID-19 demographic and rising disposable incomes have also driven more of the population to adopt pets, thus boosting the market’s growth. Globally, dogs and cats are the most common domestic pets. Hence, the number of pets in a country is usually measured by these animals. According to World Population Review 2024, the United States undoubtedly leads the world in pet ownership, with approximately 70 million domestic dogs and 74 million domestic cats.

Another characteristic of the market is the practice of collaborating with competitors to strengthen one's position and increase sales. For instance, in March 2023, Boehringer Ingelheim formed a strategic partnership with New Ruipeng Group, a leading veterinary service provider in China. This collaboration focuses on expanding Boehringer Ingelheim's presence in the East Asian veterinary market and leveraging advanced diagnostic and treatment solutions for renal diseases in pets. Another significant development came in July 2022 when Dechra Pharmaceuticals PLC acquired Piedmont Animal Health LLC for USD 210 million. This strategic acquisition aimed to bolster Dechra's product development resources, particularly in the veterinary renal diseases market.

The veterinary renal diseases market is poised for significant growth, fueled by advancements in diagnostics and treatments and increasing awareness among pet owners. Continued innovation and early detection are key to improving outcomes and quality of life for affected animals.

However, the market faces restraints due to the high cost of advanced diagnostic and treatment options, limiting accessibility for some pet owners. Additionally, the lack of awareness and education about the early detection and management of renal diseases in pets further hampers market growth.